10-Q: Femasys Inc. Reports Increased Sales and Progress in Commercialization Efforts in Q3 2024

Femasys Inc. saw a significant increase in sales and continued progress in the commercialization of its products during the third quarter of 2024, while also advancing its clinical programs.

Summary

• Femasys Inc. reported a net loss of $5.4 million for the three months ended September 30, 2024, and a net loss of $13.7 million for the nine months ended September 30, 2024.
• Sales for the quarter increased by 127.1% to $554,908 compared to $244,361 in the same period last year, driven by increased sales of FemaSeed and FemVue.
• The company's operating expenses totaled $5.5 million for the quarter and $13.8 million for the nine months ended September 30, 2024, with significant increases in sales and marketing expenses.
• Research and development expenses were $2.3 million for the quarter and $6.0 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents stood at $7.6 million as of September 30, 2024.
• Femasys has an accumulated deficit of $122.1 million as of September 30, 2024.
• The company has raised approximately $8.7 million through an at-the-market facility as of September 30, 2024.
• The company has a convertible note with a principal balance of $6.85 million as of September 30, 2024.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive news regarding sales growth, regulatory approvals, and strategic partnerships, the company's significant net losses, going concern warning, and need for additional capital raise concerns. The overall sentiment is cautiously optimistic but with significant financial risks.

Positives

• The company experienced a significant increase in sales, driven by the commercial launch of FemaSeed.
• Strategic distribution partnerships in Spain are expected to generate substantial revenue.
• Regulatory clearances and certifications were obtained for multiple products in key markets.
• The company has made progress in clinical trials for both FemaSeed and FemBloc.
• The company has secured a partnership with a prominent fertility network, Boston IVF.

Negatives

• The company reported a net loss of $5.4 million for the quarter and $13.7 million for the nine months ended September 30, 2024.
• Operating expenses increased significantly, particularly in sales and marketing, due to commercialization efforts.
• The company has an accumulated deficit of $122.1 million.
• The company's cash and cash equivalents are $7.6 million, which is not sufficient to fund operations for the next twelve months.
• The company has a going concern warning due to its current financial position.

Risks

• The company's ability to continue as a going concern is in doubt due to its current financial position.
• The company needs to raise additional capital to fund its operations and the development of FemBloc.
• There is no assurance that the company will be able to obtain additional financing on acceptable terms.
• The company's operating expenses are increasing, particularly in sales and marketing.
• The company is subject to risks associated with the development and commercialization of medical devices, including regulatory approvals and market acceptance.

Future Outlook

The company plans to finance its operations with existing cash, additional equity and/or debt financing, and revenue from the sale of FemaSeed and FemVue. The company expects losses to increase over the next few years as it advances FemBloc through clinical development. The company anticipates needing to raise additional capital to complete the development and commercialization of its product candidate.

Management Comments

• The company is focused on providing women with superior minimally-invasive, non-surgical product technologies.
• The company's mission is to improve patient care and overall health economics focused on servicing the reproductive health needs for those seeking solutions for infertility issues or permanent birth control.
• The company has an expansive intellectual property portfolio and in-house manufacturing capabilities.
• The company is exploring potential strategic partners for distribution in Europe and internationally.

Industry Context

Femasys operates in the women's health market, which has seen limited innovation in recent years. The company's products and product candidates address multi-billion dollar global market segments, offering alternatives to pharmaceutical solutions, implants, and surgery. The company is competing with established players in the fertility and birth control markets, but is differentiating itself with its minimally invasive, non-surgical approach.

Comparison to Industry Standards

• The company's FemaSeed product demonstrated a 26.3% pregnancy rate by subject in its pivotal trial, which is higher than the 6.7% pregnancy rate by cycle described in the literature for intrauterine insemination (IUI) with male factor infertility.
• The company's FemBloc product is a non-surgical, non-implant, non-hormonal in-office solution for permanent birth control, which is a different approach than traditional surgical methods or hormonal implants.
• The company's FemVue product is an alternative to the radiologic approach (hysterosalpingogram) for the diagnosis of infertility, which is a less invasive and more convenient option for patients.
• The company's products are designed to be accessible in the office, which is a more convenient and cost-effective option for patients compared to hospital-based procedures.

Related Party Transactions

• In November 2023, the company issued a $5 million convertible note and warrants to PharmaCyte Biotech, Inc., where Joshua Silverman, a member of the company's board of directors, serves as interim CEO, President, and Director.
• A family member of the CEO was employed by the company during the year ended December 31, 2023 and the nine months ended September 30, 2024 and 2023.

Stakeholder Impact

• Shareholders are impacted by the company's net losses and the need for additional capital.
• Employees are impacted by the company's financial situation and the potential for changes in operations.
• Customers are impacted by the availability of the company's products and the potential for delays in commercialization.
• Suppliers and creditors are impacted by the company's financial situation and the potential for delays in payments.

Next Steps

• The company will continue to commercialize FemaSeed in the U.S. and internationally.
• The company will continue to enroll subjects in the FINALE pivotal trial for FemBloc.
• The company will explore potential strategic partners for distribution in Europe and internationally.
• The company will seek additional financing to fund its operations and the development of FemBloc.

Key Dates

Keywords

FemaSeed, FemBloc, FemVue, infertility, birth control, medical devices, clinical trials, regulatory approvals, commercialization, sales, financing